Fiorinal

Quick links to important sections

Fiorinal

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fiorinal

Fiorinal is a prescription-only medication formulated as a fixed-dose combination product intended for oral administration, classified broadly as an analgesic combination. Its pharmacological identity relies on the synchronized action of three distinct active components to achieve a comprehensive therapeutic effect, differentiating it from single-ingredient pain relievers.


Quick Facts: Fiorinal Identity

Property Description
Active Ingredients Butalbital, Acetylsalicylic Acid (Aspirin), and Caffeine
Form Oral capsules or oral tablets
Pharmacological Class Analgesic combination (Barbiturate, NSAID, Stimulant)
Origin Synthetic chemical compounds
Type Fixed-dose combination product

What Type of Medicine is Fiorinal?

Fiorinal belongs to the analgesic combination pharmacological class. This medication incorporates Butalbital, a substance chemically classified as a barbiturate that exerts a Central Nervous System (CNS) depressant action. This distinguishes Fiorinal from many common non-barbiturate analgesics. The combination is clinically recognized for its utility in situations where pain is compounded by heightened muscle tension. This product maintains its differentiation through the inclusion of Butalbital, which makes it a controlled substance in many regions.


The Core Composition and Purpose

The medication is composed of three distinct synthetic chemical compounds serving as active ingredients: Butalbital, Acetylsalicylic Acid (ASA), and Caffeine. Acetylsalicylic Acid (or Aspirin) is an NSAID that delivers peripheral analgesic and anti-inflammatory activity. Caffeine, a CNS stimulant, functions as an adjuvant to significantly boost the overall pain-relieving efficacy of the formulation. The general purpose of this combination is to provide a multi-modal physiological effect, utilizing simultaneous sedative, analgesic, and anti-inflammatory actions. This strategic approach is leveraged to help relieve complex discomfort where single-action analgesics may be insufficient, providing a comprehensive response via a single fixed dose.

Regulatory References

  1. DailyMed (NIH)

What side effects are possible with Fiorinal ?

Possible Side Effects and Safety Information

The safety profile of Fiorinal is defined by the officially documented adverse reactions primarily affecting the Central Nervous System (CNS) and Gastrointestinal (GI) systems, reflecting the combination of Butalbital, Aspirin, and Caffeine. Safety classifications are based on government regulatory labeling and clinical surveillance data.

Adverse reactions classified as Common typically include Drowsiness, Dizziness, Lightheadedness, and Sedation, reflecting the CNS depressant effect of the Butalbital component. Other frequently documented reactions within the GI system are Nausea, Vomiting, and Abdominal pain.

Documented Serious Adverse Reactions and Constraints

The official labeling documents potential serious adverse reactions associated with the components. The Aspirin content carries risks for severe reactions, including Gastrointestinal Bleeding and rare, but serious conditions like Toxic Epidermal Necrolysis. The product is strictly contraindicated in patients with a known hypersensitivity to any component, severe hepatic or renal impairment, Porphyria, and the syndrome of Aspirin-sensitive asthma.

Time- and Population-Related Safety Notes

Safety notes specify patterns tied to duration of use. The Butalbital component is explicitly associated with a potential for developing Tolerance and Dependence when used for prolonged periods, potentially leading to Withdrawal symptoms upon cessation. For specific populations, caution is advised in older adults. Furthermore, the use of the Aspirin component in children and teenagers with viral illness is strongly linked to the risk of Reye's syndrome as noted in regulatory texts. Use during the third trimester of pregnancy is constrained due to potential fetal risks.

Overdose and Emergency Response

Overdose of Fiorinal, a fixed-dose combination product, presents a complex toxicity profile documented by regulatory authorities. Manifestations may include severe drowsiness, confusion, vomiting, stomach pain, tinnitus (ringing in the ears), or signs of internal bleeding such as bloody or black, tarry stools.

Due to the butalbital component, overdose carries the risk of profound Central Nervous System (CNS) depression, coma, and fatal outcome. The primary life-threatening risk is respiratory depression, which can be exacerbated in elderly or debilitated patients. The aspirin component poses the specific risk of Reye’s Syndrome in children and teenagers.

Official regulatory guidance mandates that immediate medical attention must be sought at once for any suspected overdose. Emergency services (911) must be contacted immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The Poison Help line should also be called.

No specific antidote is officially documented; treatment is symptomatic and supportive. Specific interventions, such as the administration of activated charcoal or monitoring of renal function, may be required, as outlined in official prescribing information.

Therapeutic Uses of Fiorinal

What Fiorinal Treats: Main Uses and Benefits

Fiorinal is commonly used to help with the relief of the symptom complex of tension (or muscle contraction) headache. This combination drug is relevant in conditions characterized by periods of heightened symptoms where additional management of discomfort is required. The core therapeutic domains include easing acute head pain, reducing associated muscular and central nervous tension, and managing minor inflammatory components.


Key Therapeutic Focus

This medication is applied in contexts where additional symptomatic support is needed, particularly for acute, episodic manifestations that create noticeable interference with daily stability. The combination is relevant for managing symptoms that interfere with daily comfort. This is relevant in situations involving symptomatic discomfort: “The medication is commonly used to help with symptom clusters that may become intense or disruptive.” It is utilized during phases where the patient experiences heightened discomfort, and the combination contributes to improved comfort during these periods. By targeting the pain, tension, and mild inflammation concurrently, Fiorinal may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability during symptomatic phases.


Quick Fact: Relief for Tense Headaches

Use Context Symptom Focus Patient Benefit
Acute Episodes Pain, Tension, Inflammation Supports functional stability
Condition Tension-type Headache Eases overall symptom load
Target Severity Heightened Symptoms Improved comfort

Regulatory References

  1. DailyMed label from the National Library of Medicine

Eligibility and Restrictions for Use

This information is based strictly on authoritative government regulatory documents from agencies like the FDA and Health Canada.

Populations that Must Not Use Fiorinal (Contraindications)

Fiorinal is contraindicated for individuals with:

  • Known hypersensitivity or intolerance to aspirin, caffeine, butalbital, or any component of the formulation.
  • Hemorrhagic diathesis (bleeding disorders), such as hemophilia or severe liver damage, or patients with peptic ulcer or other serious gastrointestinal lesions.
  • The syndrome of nasal polyps, angioedema, and bronchospastic reactivity to aspirin or other NSAIDs.
  • Porphyria or a history of substance abuse or overdosage (Canada).
  • Pregnancy during the third trimester (at or after 30 weeks gestation) due to risk of fetal ductus arteriosus closure.

Age and Condition-Specific Restrictions

  • Pediatric Use: The medicine should not be administered to children under 18 years of age (Canada). It should be used with caution in children and teenagers with chicken pox or flu (risk of Reye's syndrome).
  • Restricted Use: The drug should be prescribed with caution for the elderly or debilitated and those with severe impairment of renal or hepatic function, coagulation disorders, or head injuries. Extended use is not recommended due to butalbital's habit-forming potential.
  • Pregnancy and Lactation: Use between 20 and 30 weeks gestation is conditional and should be limited. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Fiorinal, a combination medicine containing butalbital, aspirin, and caffeine, has several documented interactions based on its individual components, as outlined in official regulatory documents. These interactions primarily involve agents that increase the risk of central nervous system (CNS) depression or affect blood clotting.

Documented Interactions

Interacting Product Category Official Constraint and Implication
CNS Depressants & Alcohol Avoid concurrent use. Additive CNS depression (e.g., increased sedation) may occur with other narcotic analgesics, general anesthetics, tranquilizers, sedative-hypnotics, and alcohol.
MAO Inhibitors Contraindicated (or use within 14 days of butalbital initiation). The CNS effects of the butalbital component may be enhanced.
Oral Anticoagulants Requires careful monitoring. May enhance the effects of anticoagulants (e.g., Warfarin) by inhibiting prothrombin formation and displacing them from protein binding sites, increasing the risk of bleeding.
Uricosuric Agents Diminished effect of agents like probenecid and sulfinpyrazone; aspirin competes with these for protein binding sites, reducing their effectiveness in treating gout.
Other NSAIDs Increased risk of gastrointestinal irritation, peptic ulceration, and bleeding due to additive effects.

Additionally, concomitant use with certain antidiabetic agents, insulin, methotrexate, or 6-mercaptopurine may enhance their effects, potentially requiring clinical oversight. Patients on chronic corticosteroid therapy may experience salicylism if corticosteroids are withdrawn due to altered renal clearance of aspirin.

Mechanism of Action

How Fiorinal Works

Fiorinal is a fixed-dose combination medication whose three active components engage distinct biological systems, resulting in a multifaceted physiological response.


Central Nervous System Modulation

The barbiturate component, butalbital, exerts its action within the central nervous system (CNS) by binding to and potentiating the inhibitory effects of GABA-A receptors. This interaction increases the duration of chloride channel opening, hyperpolarizing the neuron and regulating overactive neuronal firing patterns, which results in generalized CNS depression.


Mediator and Pathway Regulation

Acetaminophen works primarily by inhibiting cyclooxygenase (COX) enzymes, particularly in the brain and spinal cord, which decreases the production of prostaglandins. Modifying these early molecular steps within the signaling cascade limits the impact of pro-inflammatory mediator activity. The physiological consequence includes modified central processing of afferent nociceptive signals and decreased hypothalamic set-point activity.


Physiological Stimulant and Vascular Adjustment

Caffeine acts as a CNS stimulant and an inducer of vasoconstriction. It narrows blood vessels, notably within the cerebral circulation. This targeted pathway adjustment decreases cerebral blood flow, influencing the tonicity within the cranial vascular system, and may contribute to the combined pharmacological action of the components.

Dosage and Administration Information

Fiorinal (butalbital, aspirin, and caffeine) is a prescription medicine that must be taken strictly according to official guidelines for administration.

Administration and Dosing

This medication is taken orally (by mouth) in the form of a capsule. The official dosing instructions for adults define a specific quantity and frequency that must be followed:

  • Initial Dose: Take 1 or 2 capsules.
  • Frequency: Doses may be repeated every 4 hours as needed.
  • Alternative: Some regimens state to take 2 capsules at once, followed by 1 capsule every 3 to 4 hours, if necessary.

Usage Restrictions and Limits

To prevent exceeding safe levels and to mitigate the risk of physical dependence associated with butalbital, strict limits are mandated:

  • Daily Maximum: Do not take more than 6 capsules in any 24-hour period.
  • Duration: The medicine is intended for intermittent use and should not be taken continuously on a daily basis. Extended or repeated use is officially discouraged.

Discontinuation

If the medication has been taken regularly and physical dependence is suspected, the drug must not be stopped suddenly. The official guidance states that the dose should be gradually tapered to minimize withdrawal effects. Dosage reduction, such as a 25% to 50% decrease every two to four days, is the procedural step required for discontinuation in physically dependent patients.

Recent Clinical Evidence

Fiorinal: Recent Clinical Evidence

The clinical evaluation of Fiorinal has primarily focused on its use in the symptom complex of tension (or muscle contraction) headache, a condition characterized by periods of heightened symptom activity. Research for this combination was conducted using Randomized Controlled Trials (RCTs), specifically double-blind, multi-center trials. To examine the contribution of each component (Butalbital, Aspirin, and Caffeine), studies explored the formulation using a factorial design, comparing the three-component drug against individual active components and an inert placebo.

Studies monitored patient responses over defined, short time intervals during episodes where symptoms became more noticeable. The measured outcomes included patient-reported outcomes describing symptom patterns and assessments of changes in headache pain severity, physical discomfort, psychic tension, and muscle contraction. Findings describe symptom patterns observed in the adult populations during the short follow-up period, providing insight into short-term changes under the specific conditions of the trials.

The clinical evidence base is consistently relevant in trials assessing short-term or episodic symptom patterns. Research exploring symptom changes was primarily conducted over limited follow-up durations, focusing on patient response within the first four hours following a single dose. Evidence is unavailable in the regulatory record to characterize the effects or safety profile for the treatment of multiple recurrent headaches or for extended, chronic use.

Data for certain groups remain insufficient. The results apply only to the adult patients studied in the main trials. Research exploring the profile for pediatric populations (children and adolescents) is not established. Similarly, limited information has been gathered for older adults (geriatric) populations. The most significant limitation is the lack of long-term data to establish the profile of the formulation for recurrent or chronic tension headaches.

Key Studies & References

  1. Butalbital, Aspirin, and Caffeine Tablets, USP - DailyMed (National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Fiorinal (FAQ)

Q: Can I take other pain relievers (like ibuprofen) with Fiorinal?

According to official drug information, concurrent use of Fiorinal with other nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may increase the potential risk for side effects. This includes the possibility of heightened gastrointestinal irritation, bleeding, or stomach ulcers. Official sources describe this as an additive risk due to the aspirin component.


Q: Does Fiorinal lose effectiveness over time?

Regulatory documents note that the butalbital component carries a potential for developing tolerance when used for prolonged periods. The concept of tolerance indicates that over time, a diminished response may occur, potentially requiring higher amounts of the medication to achieve the initial effect. This possibility contributes to the recommendation that Fiorinal be intended only for intermittent, short-term use.


Q: Does Fiorinal treat the cause of the headache or just the symptoms?

Fiorinal is classified as an analgesic combination, and its intended purpose is to provide relief for the symptoms associated with tension headaches. The formulation works by targeting the discomfort and physical patterns of the headache, rather than treating any underlying causes of the condition.


Q: How quickly does Fiorinal start working after taking it?

Official pharmacokinetic data describes that the concentration of the active ingredients reaches its highest measured level in the bloodstream at different times. For instance, the aspirin component peaks around 40 minutes after a dose, and the butalbital component reaches its peak in approximately one and a half hours.


Q: How long does the effect of Fiorinal last?

The duration of effect is generally related to the medication's approved dosing schedule. The medicine is typically indicated for repeat dosing every four hours as needed. Official pharmacokinetic data shows that the aspirin and caffeine components have a plasma half-life of approximately three hours.


Q: What happens if I miss a scheduled time for Fiorinal?

Patient information derived from regulatory guidance provides instruction on managing a missed dose. The guidance describes that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; official patient warnings caution against doubling the doses.


Q: Is Fiorinal a type of narcotic pain medication?

Fiorinal is not classified as a narcotic (opioid) pain reliever. It contains butalbital, which is chemically classified as a barbiturate. Because of this component, regulatory agencies classify it as a Schedule III controlled substance due to its potential for dependence.


Q: Are there studies supporting the use of Fiorinal for tension headaches?

The clinical evidence base includes studies focused on the symptom complex of tension headache. These studies, described in official documents, examined the combination using randomized, placebo-controlled methods to assess its effects.


Q: Can Fiorinal be taken during pregnancy?

Official regulatory documents constrain the use of Fiorinal during pregnancy due to potential fetal risks. The medication is strictly contraindicated (not to be used) during the third trimester, which is at or after 30 weeks gestation. Use between 20 and 30 weeks gestation is also described as limited and conditional.


Q: Does Fiorinal contain codeine?

The official product information lists the active ingredients in this formulation as Butalbital, Aspirin, and Caffeine. Codeine is not included in this specific combination product.


Q: What if I take too much Fiorinal by accident?

Official guidance for accidental overdose states that immediate emergency medical services are necessary. Signs of a possible overdose may include extreme drowsiness, confusion, or seizures. The guidance directs contact with a poison control center immediately.


Q: What are the signs of an allergic reaction to Fiorinal?

Official safety information identifies several potential signs of a severe allergic reaction (hypersensitivity). These symptoms may include difficulty breathing, the development of skin rash or hives, or swelling of the face, lips, tongue, or throat.


Q: Is there a generic version of Fiorinal available?

Regulatory and patient information confirms that generic pills containing the same active ingredients (Butalbital, Aspirin, and Caffeine) are available. These generic formulations are often described as lower-cost alternatives to the brand name product.


Q: Are there foods or beverages that interact with Fiorinal?

Official patient information includes advisory statements regarding the consumption of foods and beverages that contain additional caffeine. These include products like coffee, tea, cola, and chocolate. This advisory is in place to help avoid potential symptoms of nervousness, shakiness, or an increased heart rate due to the combined stimulant effect.


Q: Does Fiorinal interact with any common antidepressant medications?

Official regulatory documents state that Fiorinal is strictly contraindicated (should not be used) for concurrent use with or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs). These are classified as a type of antidepressant medication.


Q: Does Fiorinal have any known effects on mood or anxiety?

Fiorinal contains butalbital, which is chemically classified as a sedative. As a central nervous system (CNS) depressant, it contributes to the relaxation or generalized sedative effect of the medicine.


Q: Does Fiorinal interact with birth control pills?

Regulatory-derived patient information indicates that this medication may decrease the effectiveness of hormonal birth control methods. This includes birth control pills, patches, or rings. The information highlights that alternative or backup methods may be needed to maintain effectiveness.

How should Fiorinal be stored and disposed of?

How to Store and Dispose of Fiorinal?

Fiorinal (butalbital, aspirin, and caffeine) must be stored at Controlled Room Temperature of 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The medication must be kept in a tight, light-resistant container to protect it from moisture and light, and must not be exposed to freezing or excess heat. Due to its barbiturate content, it must be kept out of the reach of children, and the packaging should utilize a child-resistant closure.

Official Disposal Guidance

Outdated or unused medicine must not be saved. Patients should consult a healthcare professional on how to dispose of any remaining medication, adhering to local regulations for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fiorinal  found in:

A-Z Index: